Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
MicroRNA (miRNA) inhibitors are small molecules that interfere with the maturation or activity of miRNAs. These noncoding RNAs of about 22 nucleotides pair with messenger RNAs (mRNAs) and repress their translation or stability. Targapremir-210, MIR96-IN-1 and SID 3712249 are listed as inhibitors of miR-210, miR-96 and miR-544. Other compounds act on the RNA-binding protein LIN28, which blocks let-7 maturation by binding its precursor and directing terminal uridylation. LIN28 inhibitor LI71 and Lin28-let-7a antagonist 1 belong to this group. The set is mixed and also contains compounds with other main targets, such as camptothecin and the peptidylarginine deiminase (PAD) inhibitor Cl-amidine.
Lin28-let-7a antagonist 1 shows a clear antagonistic effect against the Lin28-let-7a interaction with an IC50 of 4.03 μM for Lin28A-let-7a-1 interaction.
FHND5032 is an orally active miR-124 inducer that enhances miR-124 expression in macrophages. Its mechanism involves the inhibition of the PIK3R2/PI3K/Akt signaling pathway, leading to disrupted inflammatory signaling and improved macrophage reprogramming. FHND5032 has demonstrated efficacy in alleviating colitis and reducing the inflammatory burden in models of ulcerative colitis, making it a valuable reagent for research focused on inflammatory bowel diseases.
Synonyms: Temavirsen
RG-101 is a miR-122 antagonist designed to inhibit the function of miR-122, which is a crucial host factor for the replication of hepatitis C virus (HCV). This hepatocyte-targeted N-acetylgalactosamine conjugated oligonucleotide can be utilized in research focused on HCV biology and the development of antiviral therapies. Its ability to modulate miR-122 activity provides valuable insights into potential therapeutic strategies for hepatitis C infections.
Out of stock
All 3 sizes